OBIO.NASDAQOrchestra Biomed Holdings, INC

Form 4: Orchestra BioMed CFO Receives 100,000 Restricted Stock Units

Sentiment:

SEC Form 4 Filing

📋All filings for Orchestra Biomed Holdings, INC
🔒Login to Follow

Andrew Lawrence Taylor, CFO of Orchestra BioMed Holdings, Inc., was granted 100,000 restricted stock units (RSUs) on May 8, 2024, vesting over approximately three years.

Summary

  • Andrew Lawrence Taylor, the Chief Financial Officer of Orchestra BioMed Holdings, Inc., received an award of 100,000 restricted stock units (RSUs) on May 8, 2024.
  • These RSUs represent a contingent right to receive one share of common stock per RSU.
  • The RSUs vest in installments, starting with 15,000 RSUs vesting on May 20, 2025.
  • The remaining 85,000 RSUs will vest in equal installments on various dates between August 20, 2025, and May 20, 2028, contingent upon Taylor's continuous service through those dates.
  • Following the transaction, Taylor directly owns 378,363 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.

Positives

  • The grant of RSUs aligns the CFO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
  • The vesting schedule encourages continued service and commitment from the CFO.

Industry Context

Equity compensation is a common practice in the biotech industry to attract and retain key executives. The vesting schedule is designed to align management's interests with the long-term success of the company.

Comparison to Industry Standards

  • Granting RSUs to key executives is a standard practice in the biotechnology industry, similar to companies like Medtronic or Boston Scientific.
  • The vesting schedule of these RSUs, spread over approximately three years, is also typical for executive compensation packages in comparable companies.

Stakeholder Impact

  • Shareholders may view the RSU grant positively as it incentivizes the CFO to work towards increasing shareholder value.
  • Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

DateDescription
05/08/2024Date of the transaction: CFO Andrew Lawrence Taylor received 100,000 RSUs.
05/20/2025First vesting date: 15,000 RSUs will vest.
08/20/2025Second vesting date: A portion of the remaining 85,000 RSUs will vest.
11/20/2025Third vesting date: A portion of the remaining 85,000 RSUs will vest.
12/20/2025Fourth vesting date: A portion of the remaining 85,000 RSUs will vest.
05/20/2026Fifth vesting date: A portion of the remaining 85,000 RSUs will vest.
08/20/2026Sixth vesting date: A portion of the remaining 85,000 RSUs will vest.
11/20/2026Seventh vesting date: A portion of the remaining 85,000 RSUs will vest.
03/25/2027Eighth vesting date: A portion of the remaining 85,000 RSUs will vest.
05/20/2027Ninth vesting date: A portion of the remaining 85,000 RSUs will vest.
08/20/2027Tenth vesting date: A portion of the remaining 85,000 RSUs will vest.
11/20/2027Eleventh vesting date: A portion of the remaining 85,000 RSUs will vest.
03/25/2028Twelfth vesting date: A portion of the remaining 85,000 RSUs will vest.
05/20/2028Final vesting date: A portion of the remaining 85,000 RSUs will vest.
05/10/2024Date of signature by Attorney-in-Fact.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.